Agenda OHDSI Sweden Symposium 2025
The adoption of OMOP is accelerating across the world, now is a great opportunity for Sweden to jump on the train, and the global life science community welcomes us.
Welcome to join the OMOP 4 Sweden movement!
Location
Life City, Solnavägen 3H, Solna and online (link will be provided after registration)
November 5, 2025, 09:00-17:15, after-event mingle 17:15-18:00
Limited spots available at GoCo Health Innovation City in Gothenburg. Please contact Lars Lindsköld via email.
Why have we organized this event?
- Swedish health data is not leveraged to the extend it should, we want to change that! We owe it to our patients, to our healthcare staff and to our society.
- More people need to learn about OMOP, an open community-driven standard with free open-source tools that avoid vendor lock-in and enable reproducible analytics worldwide.
- To demonstrate how federated analytics works: data stays local, queries travel, enabling international collaboration while protecting privacy.
- To showcase concrete examples of real healthcare delivery, research and innovation already powered by OMOP.
- To show how OMOP complements existing health data standards (openEHR, FHIR, SNOMED CT) by providing the analytical layer.
- To position OMOP in relation to Sweden’s strategic priorities: EHDS, national life science strategy, key strategic initiatives and investments in registries and digital health.
- To build engagement and momentum for national adoption by highlighting opportunities for researchers, healthcare providers, government, and industry to collaborate.
» Christian Högberg, Host and moderator, OMOP 4 SWEDEN! leader, Passion 2 Improve Sweden
» Kristian Bolin, Professor in Health Economics, Gothenburg University
» Sofie Gustafsson, Global Director Real World Evidence Partnerships & Innovation, Pfizer
» Martin Persson, Patient Representative, Network against Cancer
» Andreas Hager, Innovation Lawyer Digitalization, Karolinska University Hospital & Patient Advocate at Upstream Dream
The Journey of OHDSI
Where have we been and where can we go together?
» Patrick Ryan, The Janssen Pharmaceutical Companies of Johnson & Johnson, Columbia University, OHDSI International
What is OMOP and OHDSI? User groups and use-cases? What are some of the OHDSI tools and methods?
» Renske Los, Erasmus MC, OHDSI Europe, OHDSI NL
» Jordan Kane, Stiftelsen Chalmers Industriteknik
The European Health Data & Evidence Network (EHDEN) Project & Foundation
» Carlos Díaz, EHDEN Foundation, CEO Synapse Research Management Partners
Harnessing Unstructured Data and Hospital Interoperability - The potential of next-generation platforms in transforming patient recruitment
» Mats Sundgren, i-HD, The European Institute for Innovation Through Health Data, IOMED
The Data Analysis & Real World Interrogation Network (DARWIN-EU)
» Talita Duarte-Salles, Erasmus MC, DARWIN-EU
OHDSI Europe and OHDSI Netherlands
» Renske Los, Erasmus MC
OHDSI Finland
» Eric Fey, TBC, Helsinki University Hospital, Helsinki University
OHDSI UK
» Alex Knight, Health Data Research UK
OHDSI Belgium
» Freija Descamps, edenceHealth NV
» Ilse Vermeulen, University of Hasselt, National Node Manager of OHDSI Belgium
OHDSI Norway
» Espen Enerly, Norwegian Institute of Public Health, Cancer Registry of Norway
The voices, experiences and recommendations from Sweden’s early OMOP adopters.
» Rickard Ljung, The Swedish Medical Products Agency (DARWIN-EU Sweden) (repr. Prof. Fredrik Nyberg, Institute of Medicine, University of Gothenburg)
» Jonas Wastesson, Karolinska Institutet, Dep. Medical Epidemiology and Biostatistics
» Niklas Norén, Uppsala Monitoring Center
How RWE can support pharmacovigilance signal management, and OMOP’s role in removing barriers
» Niklas Norén, Uppsala Monitoring Center
Global evidence generation with OMOP-harmonized clinical data: case lung cancer
» Kimmo Porkka, Professor of Personalized Cancer Medicine, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki
Development of HEARTwise Machine Learning framework to predict patient deterioration using existing OMOP CDM NEWS variables
» Freija Descamps & Lars Halvorsen, edenceHealth (representing Jan Yperman Hospital & Antwerp University Hospital)
National infastructure for secondary use of health data. Experiences from England.
» Jake Marshall, Imperial College London
Value from Nordic Health Data (VALO): A Hands-On Case Study of a pan-European Cancer Research Project Using OMOP
» Åslaug Helland, University of Oslo, Oslo University Hospital
A Data Scientist's perspective on the lessons learned
» Iiro Toppila, Data Analysis Lead, Biostatistician at Medaffcon
Panel conversation
Moderator: Christian Högberg, OMOP 4 SWEDEN! leader, Passion 2 Improve Sweden
What could more access to, and use of standardized health data mean for Sweden, its national life science strategy and our strategic initiatives?
» Michel Silvestri, Swedish eHealth Agency
» Päivi Östling, Karolinska Institutet
» Sofie Gustafsson, Pfizer
» Amy Leval, Johnson & Johnson
» Katrine Riklund, Umeå Universitet & EUCAIM
» Sebastiaan Meijer, KTH & Health Data Sweden
» Carl Jarnling, IQVIA Nordics
Panel conversation
Moderator: Sabine Koch, Introduction and panel moderator, Karolinska Institutet
Is OMOP another important piece in the jigsaw-puzzle of international health data standards?
» Daniel Karlsson, Swedish eHealth Agency
» Mikael Nyström, OpenEHR Sweden and Cambio
» Niklas Eklöv, National Board of Health and Welfare (Snomed-CT)
Christian Högberg, Host and moderator, OMOP 4 SWEDEN! leader, Passion 2 Improve Sweden
